Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), bought 1,869,162 shares at $10.70 ($20.0M) on 2022-12-12, disclosed to the SEC on 2022-12-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.70 | 934,581 | $10.0M | 50.0% |
| 2 | $10.70 | 934,581 | $10.0M | 50.0% |
| Total | $10.70 avg | 1,869,162 | $20.0M | 100% |
| Filing → |
| DYN | SELL | 2026-06-30 | $10.7M | — | Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |